Pharmacokinetics of clozapine and its metabolites in hippocampal HT22 cells

European Journal of Pharmacology

Volumn 476, Issue 3, 2003, Pages 167-172

  Heiser, Philip ^a   Schuler Springorum M ^a   Schulte, Eva ^a   Hausmann, Christiane ^a   Remschmidt, Helmut ^a   Krieg, Jürgen Christian ^a   Vedder, Helmut ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Clozapine; Hippocampus; Metabolism; Metabolite

Indexed keywords

CLOZAPINE; CLOZAPINE N OXIDE; CYTOCHROME P450 1A2; DRUG METABOLITE; MESSENGER RNA; NORCLOZAPINE;

ANALYSIS OF VARIANCE; ANALYTIC METHOD; ARTICLE; BRAIN NERVE CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG EFFECT; HIPPOCAMPUS; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; STUDENT T TEST; SUPERNATANT;

EID: 0142122062     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)02176-9     Document Type: Article

References (46)

1. Aitchison K.J., Jann M.W., Zhao J.H., Sakai T., Zaher H., Wolff K., Collier D.A., Kerwin R.W., Gonzalez F.J. Clozapine pharmacokinetics and pharmacodynamics studied with Cyp1A2-null mice. J. Psychopharmacol. 14:2000;353-359.
2. Arranz M.J., Dawson E., Shaikh S., Sham P., Sharma T., Aitchison K., Crocq M.A., Gill M., Kerwin R., Collier D.A. Cytochrome P4502D6 genotype does not determine response to clozapine. Br. J. Clin. Pharmacol. 39:1995;417-420.
3. Aymard N., Baldacci C., Leyris A., Smagghe P.O., Tribolet S., Vacheron M.N., Viala A., Caroli F. Neuroleptic-resistant schizophrenic patients treated by clozapine: clinical evolution, plasma and red blood cell clozapine and desmethylclozapine levels. Therapies. 52:1997;227-232.
4. Beyenburg S., Watzka M., Clusmann H., Blumcke I., Bidlingmaier F., Elger C.-E., Stoffel-Wagner B. Messenger RNA of steroid 21-hydroxylase (CYP21) is expressed in the human hippocampus. Neurosci. Lett. 308:2001;111-114.
5. Combs M.D., Perry P.J., Bever K.A. N-Desmethylclozapine, an insensitive marker of clozapine-induced agranulocytosis and granulocytopenia. Pharmacotherapy. 17:1997;1300-1304.
6. Dailly E., Urien S., Chanut E., Claudel B., Guerra N., Femandez C., Jolliet P., Bourin M. Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance. Prog. Neuro-psychopharmacol. Biol. Psychiatry. 26:2002;699-703.
7. Dean B., Hayes W., Opeskin K., Naylor L., Pavey G., Hill C., Keks N., Copolov D.L. Serotonin2 receptors and the serotonin transporter in the schizophrenic brain. Behav. Brain Res. 73:1996;169-175.
8. Dettling M., Sachse C., Brockmoller J., Schley J., Muller-Oerlinghausen B., Pickersgill I., Rolfs A., Schaub R.T., Schmider J. Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology (Berl.). 152:2000;80-86.
9. Eiermann B., Engel G., Johansson I., Zanger U.M., Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br. J. Clin. Pharmacol. 44:1997;439-446.
10. Fang J., Coutts R.T., McKenna K.F., Baker G.B. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn-Schmiedeberg's Arch. Pharmacol. 358:1998;592-599.
11. Grace A.A. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res. Rev. 31:2000;330-341.
12. Guitton C., Abbar M., Kinowski J.M., Chabrand P., Bressolle F. Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. J. Clin. Psychopharmacol. 18:1998;470-476.
13. Hagg S., Spigset O., Mjorndal T., Granberg K., Persbo-Lundqvist G., Dahlqvist R. Absence of interaction between erythromycin and a single dose of clozapine. Eur. J. Clin. Pharmacol. 55:1999;221-226.
14. Henning U., Loffler S., Krieger K., Klimke A. Uptake of clozapine into HL-60 promyelocytic leukaemia cells. Pharmacopsychiatry. 35:2002;90-95.
15. Henning U., Krieger K., Loffler S., Klimke A. Transport of clozapine and its major metabolites into human cells of glial and neuronal origin. Eur. Arch. Psychiatry Clin. Neurosci. 252(Suppl. 1):2002;P210. (poster presentation).
16. Huang P., Rannug A., Ahlbom E., Hakansson H., Ceccatelli S. Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the expression of cytochrome P450 1A1, the aryl hydrocarbon receptor, and the arylhydrocarbon receptor nuclear translocator in rat brain and pituitary. Toxicol. Appl. Pharmacol. 169:2000;159-167.
17. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M.F., Kleinman J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology. 8:1993;315-336.
18. Kuperberg G., Heckers S. Schizophrenia and cognitive function. Curr. Opin. Neurobiol. 10:2000;205-210.
19. Linnet K., Olesen O.V. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab. Dispos. 25:1997;1379-1382.
20. Martin C., Bean R., Rose K., Habib F., Seckl J. cyp7b1 catalyses the 7alpha-hydroxylation of dehydroepiandrosterone and 25-hydroxycholesterol in rat prostate. Biochem. J. 355:2001;509-515.
21. Morimoto B.H., Koshland D.E. Induction and expression of long- and short-term neurosecretory potentiation in a neural cell line. Neuron. 5:1990;875-880.
22. Morse D.C., Stein A.P., Thomas P.E., Lowndes H.E. Distribution and induction of cytochrome P450 1A1 and 1A2 in rat brain. Toxicol. Appl. Pharmacol. 152:1998;232-239.
23. Nadel L., Samsonovich A., Ryan L., Moscovitch M. Multiple trace theory of human memory: computational, neuroimaging, and neuropsychological results. Hippocampus. 10:2000;352-368.
24. Naylor L., Dean B., Opeskin K., Pavey G., Hill C., Keks N., Copolov D. Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine. J. Neural Transm. Gen. Sec. 103:1996;749-757.
25. Norris P.J., Hardwick J.P., Emson P.C. Regional distribution of cytochrome P450 2D1 in the rat central nervous system. J. Comp. Neurol. 366:1996;244-258.
26. Odou P., Frimat B., Fontaine B., Luyckx M., Brunet C., Robert H., Dine T., Gressier B., Cazin M., Cazin J.C. Determination of clozapine in serum by radioreceptor assay versus high-performance liquid chromatography: possible detection of hydroxy-metabolites. J. Clin. Pharm. Ther. 21:1996;337-342.
27. Ozdemir V., Kalow W., Okey A.B., Lam M.S., Albers L.J., Reist C., Fourie J., Posner P., Collins E.J., Roy R. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C→A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J. Clin. Psychopharmacol. 21:2001;603-607.
28. Ozdemir V., Kalow W., Posner P., Collins E.J., Kennedy J.L., Tang B.K., Albers L.J., Reist C., Roy R., Walkes W., Afra P. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. J. Clin. Psychopharmacol. 21:2001;398-407.
29. Prior T.I., Chue P.S., Tibbo P., Baker G.B. Drug metabolism and atypical antipsychotics. Eur. Neuropsychopharmacol. 9:1999;301-309.
30. Raaska K., Neuvonen P.J. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole. Eur. J. Clin. Pharmacol. 54:1998;167-170.
31. Rane A., Liu Z., Levol R., Bjelfman C., Thyr C., Ericson H., Hansson T., Henderson C., Wolf C.R. Differential effects of neuroleptic agents on hepatic cytochrome P-450 isozymes in the male rat. Biochim. Biophys. Acta. 1291:1996;60-66.
32. Remschmidt H., Schulz E., Martin M. An open trial of clozapine in thirty-six adolescents with schizophrenia. J. Child Adolesc. Psychopharmacol. 4:1994;31-41.
33. Riedl A.G., Watts P.M., Douek D.C., Edwards R.J., Boobis A.R., Rose S., Jenner P. Expression and distribution of CYP2C enzymes in rat basal ganglia. Synapse. 38:2000;392-402.
34. Scarr E., Copolov D.L., Dean B. A proposed pathological model in the hippocampus of subjects with schizophrenia. Clin. Exp. Pharmacol. Physiol. 28:2001;70-73.
35. Schoedel K.A., Sellers E.M., Tyndale R.F. Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. Biochem. Pharmacol. 62:2001;1025-1036.
36. Schulz E., Fleischhaker C., Remschmidt H. Determination of clozapine and its major metabolites in serum samples of adolescent schizophrenic patients by high performance liquid chromatography. Data from a prospective clinical trial. Pharmacopsychiatry. 28:1995;20-25.
37. Schulz E., Fleischhaker C., Clement H.W., Remschmidt H. Blood biogenic amines during clozapine treatment of early-onset schizophrenia. J. Neural Transm. 104:1997;1077-1089.
38. Seeman P. Receptor Tables, vol. 2, Drug Dissociation Constants for Neuroreceptors and Transporters. 1993;SZ Research, Toronto.
39. Siegle I., Fritz P., Eckhardt K., Zanger U.M., Eichelbaum M. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics. 11:2001;237-245.
40. Stoffel-Wagner B., Watzka M., Schramm J., Bidlingmaier F., Klingmuller D. Expression of CYP19 (aromatase) mRNA in different areas of the human brain. J. Steroid Biochem. Mol. Biol. 70:1999;237-241.
41. Taylor D., Bodani M., Hubbeling A., Murray R. The effect of nefazodone on clozapine plasma concentrations. Int. Clin. Psychopharmacol. 14:1999;185-187.
42. Tindberg N., Ingelman-Sundberg M. Expression, catalytic activity, and inducibility of cytochrome P450 2E1 (CYP2E1) in the rat central nervous system. J. Neurochem. 67:1996;2066-2073.
43. Upadhya S.C., Tirumalai P.S., Boyd M.R., Mori T., Ravindranath V. Cytochrome P4502E (CYP2E) in brain: constitutive expression, induction by ethanol and localization by fluorescence in situ hybridization. Arch. Biochem. Biophys. 373:2000;23-34.
44. Vedder H., Bening-Abu-Shach U., Languillon S., Krieg J.C. Regulation of glucocorticoid receptor-mRNA in human blood cells by amitriptyline and dexamethasone. J. Psychiatr. Res. 33:1999;303-308.
45. Watzka M., Bidlingmaier F., Schramm J., Klingmuller D., Stoffel-Wagner B. Sex- and age-specific differences in human brain CYP11A1 mRNA expression. J. Neuroendocrinol. 11:1999;901-905.
46. Young C.D., Meltzer H.Y., Deutch A.Y. Effects of desmethylclozapine on Fos protein expression in the forebrain: in vivo biological activity of the clozapine metabolite. Neuropsychopharmacology. 19:1998;99-103.